NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Star Cement Appoints Tushar Bhajanka as MD & CEO; Prem Kumar Bhajanka Named Vice Chairman
Star Cement has announced a leadership transition, elevating Mr. Tushar Bhajanka to Managing Director & CEO for a three-year term effective May 22, 2026. His father, Mr. Prem Kumar Bhajanka, has transitioned from Managing Director to Vice Chairman & Managing Director. The board also approved the audited financial results for the year ended March 31, 2026, which received an unmodified audit opinion. This move formalizes a succession plan within the promoter family, placing the younger generation in the primary executive role.
முக்கிய அம்சங்கள்
Mr. Tushar Bhajanka (29) appointed as MD & CEO for a 3-year term ending May 21, 2029.Mr. Prem Kumar Bhajanka (68) transitioned to Vice Chairman & Managing Director with immediate effect.Audited FY26 financial results approved with an unmodified opinion by statutory auditors Singhi & Co.Mr. Prem Kumar Bhajanka holds 4,34,99,400 equity shares in the company as of March 31, 2026.M/s B. G. Chowdhury & Co. re-appointed as Cost Auditors for the 2026-27 financial year.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's strategic direction under the new CEO's leadership. The transition appears to be a planned family succession and is unlikely to cause immediate operational disruption.
Megastar Foods FY26 Net Profit Surges 142% to ₹9.16 Cr; Annual Revenue Up 52%
Megastar Foods reported a stellar annual performance for FY26, with standalone revenue rising 52.1% YoY to ₹532.58 crore. The company's net profit for the full year more than doubled, jumping 142.7% to ₹9.16 crore from ₹3.78 crore in FY25. While Q4 FY26 revenue grew 21.9% YoY, net profit for the quarter saw a sequential decline of 29.2% compared to Q3 FY26. Financial health improved as the debt-to-equity ratio dropped to 0.70 and EPS rose to ₹8.11.
முக்கிய அம்சங்கள்
Annual revenue from operations jumped 52.1% YoY to ₹53,257.72 lakhs in FY26.Full-year standalone net profit surged 142.7% to ₹916.19 lakhs from ₹377.56 lakhs in FY25.Q4 FY26 revenue grew 21.9% YoY to ₹14,606.29 lakhs, though Q4 profit fell 29.2% sequentially.Debt-to-equity ratio improved to 0.70 from 0.84, indicating a stronger balance sheet.Annual Earnings Per Share (EPS) increased significantly to ₹8.11 from ₹3.34 in the previous year.
👀 கவனிக்க வேண்டியவை
Investors should view the massive annual profit growth and improving debt profile as strong positives for this small-cap stock. However, monitor the sequential margin pressure in Q4 to see if rising raw material costs are becoming a persistent trend.
Strides Pharma FY26 Revenue Hits ₹48.6B; Record EPS of ₹56 with 19% EBITDA Margin
Strides Pharma reported a steady FY26 with revenues reaching INR 48,587 million, driven by a robust 21% growth in Ex-US markets. The company achieved its highest-ever EPS of INR 56, supported by a 19% EBITDA margin and significant operational leverage. While the US business faced headwinds from a weak flu season, the Ex-US segment now contributes nearly 50% of Q4 revenue, indicating successful diversification. Management has recommended a dividend of INR 5 per share and appointed Ramaraju as Executive Director to oversee global operations.
முக்கிய அம்சங்கள்
FY26 Revenue grew 6.4% YoY to INR 48,587 million, with Ex-US markets growing at 21%.EBITDA margins expanded to 19%, a 400 bps improvement over the last three years.Reported record EPS of INR 56 for FY26, with a strong Q4 exit run rate of INR 14.7.ROCE improved significantly to 15.76% from single digits just two years ago.Recommended a dividend of INR 5 per share and announced the appointment of a new Executive Director.
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of the Sandoz portfolio in Africa and the company's progress toward its $400M US revenue target. The shift towards a diversified, high-margin Ex-US portfolio provides a more resilient earnings base.
The US-FDA concluded a routine current Good Manufacturing Practices (cGMP) inspection at Strides Pharma's flagship facility in Bangalore on May 20, 2026. The inspection, which lasted nine days starting May 12, resulted in the issuance of a Form 483 with five observations. The company has committed to responding to these observations within the stipulated timeframe to resolve the regulator's concerns. As this is a flagship site, the final classification of these observations will be critical for future US product approvals.
முக்கிய அம்சங்கள்
Routine US-FDA cGMP inspection conducted at the Bangalore flagship facility from May 12 to May 20, 2026.The inspection concluded with the issuance of a Form 483 containing 5 observations.The Bangalore site is a critical manufacturing hub for the company's US market operations.Strides Pharma will submit a formal response to the US-FDA within the required regulatory timeline.Final impact depends on whether the observations are classified as procedural (VAI) or serious (OAI).
👀 கவனிக்க வேண்டியவை
Investors should wait for the company's update on the nature of the observations and the subsequent Establishment Inspection Report (EIR). While 5 observations are common, any escalation to an 'Official Action Indicated' (OAI) status could impact the stock's valuation and product pipeline.
Strides Pharma Elevates COO to Board; Promoter Director Moves to Non-Executive Role
Strides Pharma Science Limited has announced a leadership reshuffle effective June 1, 2026, aimed at professionalizing its management. The current COO, Venkata Seetharama Raju Pakalapati, who has over 18 years of experience with the group, is being elevated to the Board as an Executive Director for a three-year term. Simultaneously, Aditya Arun Kumar, a member of the promoter group, will transition from an executive role to a Non-Executive Director position. The company also expanded its Senior Management Personnel (SMP) list to include heads of HR and Manufacturing Operations.
முக்கிய அம்சங்கள்
Venkata Seetharama Raju Pakalapati (COO) elevated to Executive Director for a 3-year term starting June 1, 2026Aditya Arun Kumar transitions from Executive Director to Non-Executive Director to further professionalize managementNandini Matiyani (EVP-HR) and Ariff Khan (EVP-Manufacturing) nominated as Senior Management Personnel (SMP)The restructured Board will consist of 9 directors, including 5 Independent Directors and 1 Managing Director & Group CEO
👀 கவனிக்க வேண்டியவை
Investors should view the transition of the promoter-family member to a non-executive role as a positive step toward institutionalizing professional governance. Monitor the company's operational efficiency under the newly elevated Executive Director who now oversees global manufacturing and supply chain.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Strides Pharma Announces Board Restructuring and Management Appointments Effective June 2026
Strides Pharma Science Limited has announced a significant restructuring of its leadership team effective June 1, 2026. Current COO Venkata Seetharama Raju Pakalapati, an 18-year veteran of the company, is being elevated to Executive Director for a three-year term. In a move to further professionalize management, Aditya Arun Kumar will transition from an executive role to a Non-Executive Director position. Additionally, the company has nominated two new Senior Management Personnel (SMP) to oversee HR and Manufacturing Operations, maintaining a board of 9 directors including 5 independent members.
முக்கிய அம்சங்கள்
Venkata Seetharama Raju Pakalapati (Ram) elevated from COO to Executive Director for a 3-year term starting June 1, 2026Aditya Arun Kumar transitions from Executive Director to Non-Executive Director to enhance professional managementNandini Matiyani (EVP HR) and Ariff Khan (EVP Manufacturing) nominated as Senior Management PersonnelThe board will consist of 9 members, including 5 Independent Directors and 1 Managing Director & Group CEORestructuring is part of a comprehensive succession planning framework and internal talent promotion
👀 கவனிக்க வேண்டியவை
Investors should view these changes as a planned transition towards professional management and internal succession. No immediate action is required, but monitor the impact of the new executive leadership on operational efficiency.
Strides Pharma Receives NCLT Approval for Arco Lab Subsidiary Demerger
Strides Pharma Science Limited has received approval from the NCLT Bengaluru Bench for a Scheme of Arrangement involving its wholly owned subsidiaries. The scheme entails the demerger of Arco Lab Private Limited's Life Sciences and Digital Innovation businesses into Pivot Path Private Limited. Upon the scheme becoming effective, Pivot Path will become a direct wholly owned subsidiary of Strides Pharma. The appointed date for this demerger is fixed as April 10, 2025, and the company is currently awaiting the certified order copy to finalize the process.
முக்கிய அம்சங்கள்
NCLT Bengaluru Bench approved the demerger scheme on May 18, 2026, with the order published on May 20, 2026.The Life Sciences and Digital Innovation businesses of Arco Lab will be transferred to Pivot Path Private Limited.The appointed date for the vesting of the demerged undertaking is April 10, 2025.Pivot Path will allot equity shares to Strides Pharma Science Limited as per the share entitlement ratio in the scheme.Post-restructuring, Pivot Path will transition from a step-down subsidiary to a direct wholly owned subsidiary of Strides.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward corporate streamlining and operational efficiency. Monitor the announcement of the effective date and any subsequent updates on the share allotment process.
Blue Star to Acquire Remaining 51% Stake in Blue Star Qatar for up to ₹50 Lakh
Blue Star Limited has approved the acquisition of the remaining 51% shareholding in its subsidiary, Blue Star Qatar W.L.L. (BSQ), from its local partner Al Malki Trading & Contracting Co. Although Blue Star already held 95% economic interest and management control, this move will make BSQ a wholly-owned subsidiary. The acquisition follows regulatory changes in Qatar that now permit 100% foreign ownership. The total consideration is capped at ₹50 lakh, and the transaction is expected to be completed within eight months.
முக்கிய அம்சங்கள்
Acquisition of 51% stake in Blue Star Qatar W.L.L. to convert it into a wholly-owned subsidiaryTotal cash consideration for the 51% stake is capped at ₹50 lakhBlue Star Qatar reported a turnover of QAR 25 million for FY26, down from QAR 53 million in FY24The move simplifies the corporate structure following Qatar's regulatory shift to allow 100% foreign ownershipTransaction is subject to approvals from the RBI and Qatari authorities, with an 8-month completion target
👀 கவனிக்க வேண்டியவை
This is a minor structural simplification with negligible financial impact on Blue Star's consolidated performance. Investors should remain focused on the company's primary growth drivers in the Indian cooling and MEP markets.
Strides Pharma Elevates COO to Executive Director; Promoter Transitions to Non-Executive Role
Strides Pharma Science Limited has announced a leadership reshuffle effective June 1, 2026, aimed at professionalizing management and strengthening its board. Current COO Venkata Seetharama Raju Pakalapati, who has been with the group for over 18 years, will be elevated to Executive Director for a three-year term. Aditya Arun Kumar, a member of the promoter group, will transition from his executive role to a Non-Executive Director position. Additionally, two Executive VPs have been nominated as Senior Management Personnel to bolster the company's leadership framework.
முக்கிய அம்சங்கள்
COO Venkata Seetharama Raju Pakalapati promoted to Executive Director and KMP for a 3-year term starting June 1, 2026.Aditya Arun Kumar transitions from Executive Director to Non-Executive Director to further professionalize management.Nandini Matiyani (HR) and Ariff Khan (Manufacturing) inducted as Senior Management Personnel (SMP).The reshuffle is part of a comprehensive succession planning framework and internal talent promotion strategy.
👀 கவனிக்க வேண்டியவை
These changes reflect a move toward a more professionalized management structure and internal succession. Investors should monitor if this transition leads to improved operational efficiency in global technical operations.
Strides Pharma Reshuffles Board: COO Ramaraju PVS Promoted to Executive Director
Strides Pharma Science Limited has announced a strategic management reshuffle effective June 1, 2026, aimed at professionalizing its leadership and implementing a succession framework. Current COO Ramaraju PVS, who has been with the company for 18 years, is being elevated to the Board as an Executive Director for a three-year term. Simultaneously, Aditya Arun Kumar, a member of the promoter group, will transition from an executive role to a Non-Executive Director position. The company also appointed Nandini Matiyani as Group CHRO and Ariff Khan as Senior Management Personnel to strengthen its executive layer.
முக்கிய அம்சங்கள்
Ramaraju PVS (COO) elevated to Executive Director and Key Managerial Personnel for a 3-year term starting June 1, 2026.Aditya Arun Kumar transitions from Executive Director to Non-Executive Director to further professionalize management.Nandini Matiyani, with over 20 years of HR experience, redesignated as Group CHRO and Senior Management Personnel.Ariff Khan, Executive VP of Manufacturing Operations, nominated as Senior Management Personnel.The reshuffle follows a Board meeting held on May 18, 2026, and is subject to shareholder approval.
👀 கவனிக்க வேண்டியவை
Investors should view the promotion of an internal veteran to the board and the promoter's transition to a non-executive role as a positive step toward professional governance. No immediate action is required, but monitor the company's operational efficiency under the new leadership structure.
Strides Pharma Recommends ₹5 Final Dividend for FY26 Following Audited Results Approval
Strides Pharma Science Limited has recommended a final dividend of ₹5 per equity share (50% of face value) for the financial year ended March 31, 2026. The Board also approved the audited standalone and consolidated financial results for the same period with an unmodified auditor's opinion. Key subsidiaries contributed significantly, with three audited entities reporting a combined revenue of ₹8,968 million and a net profit of ₹736 million. The dividend is subject to shareholder approval at the upcoming Annual General Meeting.
முக்கிய அம்சங்கள்
Recommended final dividend of ₹5 per equity share of ₹10 each (50% payout rate)Audited consolidated financial results for FY26 approved with an unmodified auditor opinionThree audited subsidiaries reported total revenue of ₹8,968 million and net profit of ₹736 millionTotal assets for the audited subsidiaries stood at ₹10,224 million as of March 31, 2026Dividend to be paid within 30 days from the date of shareholder approval at the AGM
👀 கவனிக்க வேண்டியவை
Investors should look out for the upcoming record date announcement to qualify for the ₹5 dividend. The unmodified audit report and steady dividend payout suggest stable financial health for the company.
Strides Pharma FY26 Operational PAT Jumps 50% to ₹5,181m; Dividend of ₹5 Declared
Strides Pharma Science Limited reported a robust financial performance for FY26, with Operational PAT surging 50.3% YoY to ₹5,181m. Revenue grew by 6.4% to ₹48,587m, largely driven by a 21% growth in Ex-US markets which reached $254m. The company demonstrated strong financial discipline, improving its EBITDA margin to 19% and reducing its Net Debt/EBITDA ratio to 1.55x. A dividend of ₹5 per share has been recommended, reflecting management's confidence in sustainable growth.
முக்கிய அம்சங்கள்
FY26 Operational PAT grew 50.3% YoY to ₹5,181m with Operational EPS rising to ₹56.2.Ex-US markets revenue grew 21% YoY to $254m, offsetting a flat US market performance of $284m.EBITDA margins expanded by 140bps YoY to 19.0% due to focus on high-margin products.Net Debt/EBITDA improved to 1.55x from 1.90x, despite a ₹1,115m adverse currency impact.Board recommended a dividend of ₹5 per share for the financial year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and successful debt reduction, which strengthen the balance sheet. The strong growth in non-US regulated markets provides a diversified revenue stream, making the stock attractive for long-term pharmaceutical sector exposure.
Starteck Finance Recommends Rs 0.25 Dividend; Promoters Waive Payout Rights
Starteck Finance has recommended a final dividend of Rs 0.25 per equity share (2.5% of face value) for the financial year ended March 31, 2026. A significant highlight of this announcement is that the Promoter and Promoter Group have voluntarily waived their rights to receive this dividend. The company also approved its audited financial results for FY26, which received an unmodified (unqualified) opinion from the auditors. Additionally, the board has proposed the appointment of M/s. Bagaria & Co. LLP as the new statutory auditors for a five-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 0.25 per equity share of Face Value Rs 10.Promoter and Promoter Group have waived their rights to receive the dividend for FY26.Statutory Auditors issued an unmodified (unqualified) opinion on the FY26 financial statements.Proposed appointment of M/s. Bagaria & Co. LLP as Statutory Auditors for a 5-year term starting from the 41st AGM.Re-appointed M/s Sandeep V. Chavan and Co. as Internal Auditors for the Financial Year 2026-27.
👀 கவனிக்க வேண்டியவை
The promoter dividend waiver is a positive signal for minority shareholders as it preserves cash for the company while rewarding public investors. Shareholders should monitor the upcoming AGM for the final approval of the dividend and auditor appointments.
Starteck Finance Recommends Re. 0.25 Dividend; Appoints New Statutory Auditors
Starteck Finance Limited approved its FY2026 audited financial results with an unmodified audit opinion from current auditors. The board recommended a final dividend of 2.5% (Re. 0.25 per share), though the promoter group has notably waived their right to receive this payout. Furthermore, M/s. Bagaria & Co. LLP has been appointed as the new statutory auditors for a five-year term, subject to shareholder approval at the upcoming AGM. The company also re-appointed its internal auditor for the 2026-27 financial year.
முக்கிய அம்சங்கள்
Recommended final dividend of 2.5% (Re. 0.25 per share) for the financial year ended March 31, 2026.Promoter and Promoter Group have waived their rights to receive the dividend payout.Appointment of M/s. Bagaria & Co. LLP as Statutory Auditors for a 5-year term from the 41st AGM to the 46th AGM.Current Statutory Auditors issued an unmodified (unqualified) opinion on both Standalone and Consolidated FY26 financials.Re-appointment of M/s Sandeep V. Chavan and Co. as Internal Auditor for the Financial Year 2026-27.
👀 கவனிக்க வேண்டியவை
The promoter's waiver of dividends is a positive signal of commitment to the company's cash reserves. Investors should monitor the transition to the new statutory auditor to ensure continued reporting transparency.
Blue Star Q4 FY26 Revenue Hits Record ₹4,072 Cr; Recommends ₹8.5 Dividend
Blue Star reported its highest-ever quarterly revenue of ₹4,072 crore in Q4 FY26, marking a 1.3% YoY growth despite a challenging year. While annual net profit for FY26 declined by 4.3% to ₹527.3 crore due to supply chain headwinds and a weak initial summer, the company's order book remains robust at ₹6,923 crore. The Board has recommended a dividend of ₹8.5 per share. Management expressed cautious optimism for FY27, citing a strong start to the summer season in April 2026.
முக்கிய அம்சங்கள்
Q4 FY26 consolidated revenue grew 1.3% YoY to ₹4,072 crore, while EBITDA margins improved to 8%.Full-year FY26 revenue increased 3.6% to ₹12,402 crore, though net profit fell to ₹527.3 crore.The carried forward order book grew by 10.5% YoY to reach ₹6,923 crore as of March 31, 2026.Unitary Products (Segment 2) margins improved to 10.4% in Q4 FY26 from 8.4% in the previous year.Board recommended a dividend of ₹8.5 per share for the financial year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should focus on the recovery in the room air conditioner segment and the strong order book in electromechanical projects. While Q4 showed margin improvement, watch for the impact of rising input costs and geopolitical supply chain disruptions in FY27.
Sanstar Commissions Dhule Capacity Expansion; Total Capacity Reaches 2,350 TPD
Sanstar Limited has successfully commissioned its expanded native starch manufacturing capacity at the Dhule facility, doubling its total installed capacity from 1,100 TPD to 2,350 TPD. The project fully utilized Rs. 1,816 million of IPO proceeds and exceeded the original expansion target of 1,000 MTPD by achieving 1,250 MTPD. While the native starch phase is now operational, the high-value derivatives facility is expected to be commissioned in FY2026-27. This expansion positions Sanstar as the second-largest maize-based specialty products manufacturer in India.
முக்கிய அம்சங்கள்
Total installed capacity increased significantly from 1,100 TPD to 2,350 TPDFully utilized Rs. 1,816 million of IPO proceeds for the Dhule facility expansionAchieved 1,250 MTPD capacity addition, exceeding the initial IPO plan of 1,000 MTPDDerivatives facility phase is on track for commissioning within FY2026-27Strategic location in Dhule offers logistical advantages for both domestic sourcing and exports
👀 கவனிக்க வேண்டியவை
Investors should monitor the capacity utilization rates and revenue growth in the coming quarters as the new capacity ramps up. The upcoming derivatives facility in FY27 will be a critical driver for margin expansion through value-added products.
Blue Star Q4 Net Profit Rises 17% to ₹227 Cr; FY26 Dividend Recommended at ₹8.5 Per Share
Blue Star reported a modest 1.3% revenue growth in Q4FY26 to ₹4072.06 cr, though net profit surged 17.1% to ₹227.18 cr driven by improved EBITDA margins of 8.0%. For the full year FY26, the company faced headwinds with net profit declining 10.8% to ₹527.33 cr, primarily due to a challenging environment and exceptional items related to labor codes. The order book remains healthy at ₹6923 cr, up 10.5% YoY, providing revenue visibility for the upcoming year. The Board recommended a dividend of ₹8.5 per share, slightly lower than the previous year's ₹9.
முக்கிய அம்சங்கள்
Q4FY26 Net Profit grew 17.1% YoY to ₹227.18 cr, while Revenue saw a marginal 1.3% increase to ₹4072.06 cr.Full-year FY26 Net Profit declined by 10.8% to ₹527.33 cr despite a 3.6% growth in total revenue to ₹12401.99 cr.Carried-forward order book grew 10.5% to ₹6923 cr as of March 31, 2026, with strong Q4 order inflows in the Projects segment.Unitary Products (AC segment) margins improved significantly to 10.4% in Q4 from 8.4% YoY due to cost rationalization.Recommended dividend of ₹8.5 per share for FY26, representing a slight decrease from ₹9.0 in FY25.
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the margin expansion in the Unitary Products segment and the execution of the ₹6,923 cr order book. While full-year profits were down, the strong Q4 performance and pickup in summer demand in April 2026 suggest a potential recovery in FY27.
Blue Star Q4 FY26 EBITDA Grows 16.8% to ₹326 Cr; Revenue Hits ₹4,072 Cr
Blue Star reported a steady Q4 FY26 with revenue growing marginally to ₹4,072 crore, while EBITDA saw a significant 16.8% increase to ₹326 crore. The Unitary Products segment (Room ACs) showed margin improvement to 10.4% despite stagnant growth in deep freezers. However, full-year EPS declined to ₹25.65 from ₹28.76, impacted by a ₹38 crore exceptional one-time charge related to new labor codes. The company maintains a healthy balance sheet with a net cash position of ₹175 crore and a low debt-equity ratio of 0.18.
முக்கிய அம்சங்கள்
Q4 FY26 EBITDA increased to ₹326 crore from ₹279 crore in the previous year, with margins improving to 8.0%.Unitary Products EBIT margins improved significantly to 10.4% in Q4 FY26 from 8.4% YoY.Electro-Mechanical Projects (EMP) order bookings grew by 35% driven by demand from Data Centers and Factories.Full-year FY26 revenue reached ₹12,402 crore, though EPS fell to ₹25.65 due to a ₹38 crore exceptional gratuity impact.Net cash position decreased to ₹175 crore from ₹640 crore YoY, while the debt-equity ratio remains low at 0.18.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin recovery in the EMP segment and the scalability of the US/Europe expansion. While Q4 was strong, the full-year earnings dip and lower net cash suggest a need for a cautious outlook on immediate valuation upside.
Blue Star Q4 FY26 Revenue Grows 12% to ₹2,790 Cr; EBITDA Margins Expand to 8%
Blue Star reported a steady Q4 FY26 with revenue growing 12% YoY to ₹2,790 crore and EBITDA margins improving to 8% from 7% in the previous year. While the full-year revenue grew modestly by 3.6% to ₹12,402 crore, the company faced a one-time exceptional hit of ₹38 crore due to new labor code provisions affecting full-year EPS. Segment 1 (EMP) saw strong order booking growth of 35% in Q4, while Segment 2 (Unitary Products) margins improved significantly to 10.4%. The company maintains a healthy balance sheet with a low debt-equity ratio of 0.18.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue increased 12% YoY to ₹2,790 crore, with EBITDA rising 16.8% to ₹326 crore.Unitary Products (Room ACs) segment EBIT margins improved to 10.4% in Q4 from 8.4% YoY.Electro-Mechanical Projects (EMP) saw a robust 35% growth in order bookings during the quarter.Full-year FY26 results were impacted by a ₹38 crore exceptional charge for gratuity and leave encashment.Net cash position decreased to ₹175 crore from ₹640 crore, while Debt-Equity ratio remains low at 0.18.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong margin recovery in the Unitary Products segment and the robust order pipeline in EMP. The stock remains a solid play on India's cooling and infrastructure growth, though full-year growth was slightly muted due to one-off costs.
Blue Star Recommends ₹8.5 Dividend; Approves Audited FY26 Financial Results
Blue Star's Board has recommended a final dividend of ₹8.5 per equity share (425% of face value) for the financial year ended March 31, 2026. The company approved its audited financial results for FY26, which received an unmodified opinion from statutory auditors Deloitte Haskins & Sells LLP. The record date for the dividend is set for July 17, 2026, with the payout expected after the Annual General Meeting on August 6, 2026. This announcement signals a steady return to shareholders alongside the completion of the fiscal year.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹8.5 per equity share of ₹2 face value for FY26.Fixed July 17, 2026, as the Record Date for determining dividend eligibility.Approved audited standalone and consolidated financial results for the year ended March 31, 2026.Statutory auditors issued an unmodified audit report, confirming financial transparency.The 78th Annual General Meeting (AGM) is scheduled for August 6, 2026.
👀 கவனிக்க வேண்டியவை
Investors seeking dividend income should ensure they hold shares by the record date of July 17, 2026. The clean audit report and substantial dividend payout suggest stable financial health for the company.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
